Of four wild-type strains (Nakayama-original, SA14, 826309 and Beijing-1) of Japanese encephalitis (JE) virus that were passaged six times in HeLa cells (HeLa p6), two (Nakayama-original and 826309) became attenuated for mice. In the case of strain Nakayamaoriginal, the virulence for mice was markedly reduced and attenuation was retained on passage in primary chicken embryo fibroblast, LLC-MK2 and C6/36 cells. The binding of non-HeLa-passaged Nakayama virus to mouse brain membrane receptor preparations could be differentiated from binding by Nakayama HeLa p6 virus, suggesting that the envelope (E) protein is involved in the attenuated phenotype. Both of the attenuated viruses can be distinguished from the virulent non-HeLapassaged parental viruses by examination with E protein reactive vaccine and wild-type-specific monoclonal antibodies (MAbs). The vaccine-specific MAb V23, which is only reactive with the SA14 series of live vaccine viruses, recognized the HeLa cell-attenuated Nakayama-original and 826309 viruses, whereas two wild-type-specific MAbs (MAbs K13 and K39) lost reactivity. Comparison of the nucleotide sequences of the structural protein genes of the 826309 and Nakayama-original virulent parent and attenuated HeLa p6 viruses revealed that the viruses differed by 37 and 46 nucleotides coding for eight and nine amino acid mutations, respectively. However, other than one amino acid in the E protein, the membrane and E protein amino acid sequences of the two attenuated HeLa p6 viruses were identical.
Introduction
Japanese encephalitis (JE) virus is a mosquito-borne flavivirus and a major public health problem in many Asian countries (Rosen, 1986) . The virus particle contains one single-stranded, positive-sense RNA mol-ecule approximately 11 kb in length and three structural proteins; capsid (C), membrane (M) and envelope (E) (McAda et al., 1987; Sumiyoshi et al., 1987; Hashimoto et al., 1988; Nitayaphan et al., 1990) . The E protein is believed to be a major determinant of virus pathogenicity.
The molecular basis of the attenuation of neurovirulence of JE virus is not understood. The genomes of the attenuated vaccine viruses SA14-14-2 [primary hamster kidney (PHK) and primary dog kidney (PDK) cell derivatives] and SA14-2-8, and their wild-type parental strain SA14 have been sequenced and compared (Nitayaphan et al., 1990; Aihara et al., 1991 ; Ni et al., 1995) . It was found that the SA14-14-2/PDK derivative differed from the wild-type parent virus SA14 by 47 nucleotides coding for 17 amino acid substitutions (Nitayaphan et al., 1990; Ni et al., 1995) : SA14-14-2/PHK vaccine differed from SA14 by 57 nucleotides coding for 24 amino acid substitutions (Aihara et al., 1991) and SA14-2-8 vaccine differed from SA14 by 39 nucleotides and 18 amino acids (Ni et al., 1995) . Although there are relatively few nucleotide changes, those specifically involved in attenuation and/or viru-lence still remain to be identified due to the large number of passages separating the attenuated variants from their wild-type parent virus [see Ni et al. (1994) for passage history]. Other studies, involving isolation and sequencing of monoclonal antibody (MAb) neutralization resistant mutants (Cecilia & Gould, 1991 ; Hasegawa et al., 1992) , have identified epitopes in the E protein associated with virus pathogenicity.
Hardy (1963) demonstrated that mosquito-borne wildtype yellow fever virus strain Asibi lost the ability to cause viscerotropic disease in monkeys following six passages in HeLa cells. We confirmed and extended these observations and showed that, following six passages in HeLa cells, strain Asibi also lost the ability to cause neurotropic disease in mice and lost mosquito competence Miller & Adkins, 1988) . Further studies showed that three strains of the mosquito-borne pantropic West Nile virus could also be attenuated in this way (Dunster et al., 1990) . Thus, we proposed that mosquito-borne flaviviruses could be attenuated following very few passages in HeLa cells.
In this paper we describe the attenuation of some, but not all, strains of JE virus following few passages in HeLa cells. Attenuation was accompanied by amino acid mutations, loss of wild-type-specific and acquisition of vaccine-specific epitopes on the E protein, and altered cell-binding activity.
Methods
Viruses. The four wild-type strains of JE virus, Nakayama-original (Nakayama-O), SA14, Beijing-1 and 826309, were obtained from the Center for Disease Control (Fort Collins, Colorado, USA) and have been described previously (Wills et al., 1992) . '. HeLa cells (Flow, UK) were grown in Eagle's Minimum Essential Medium (EMEM) supplemented with 10 % fetal calf serum (FCS) (Gibco), penicillin and streptomycin (Sigma), L-glutamine (Sigma) and non-essential amino acids (Sigma) according to the manufacturer's instructions. Passage was performed on 90 %-100 % confluent cell monolayers in 25 cm 2 tissue culture flasks by infection of cell monolayers with the virus at a multiplicity of infection (m.o.i.) of 5. After 30 min incubation at room temperature, EMEM containing 1% FCS was added to the infected cell cultures which were then incubated at 37 °C. Virus was harvested at 90 % cytopathic effect (CPE) or 3 days post-infection (whichever was the shorter time). Cell debris was removed by centrifugation at 2000 r.p.m. for 5 min and the virus was stored at -70 °C. The same procedure was used to passage the virus five more times in HeLa cells. Subconfluent monolayers of chicken embryo fibroblast (CEF) cells, mosquito C6/36 cells and monkey kidney LLC-MK2 cells were used to propagate the Nakayama HeLa p6 virus using an m.o.i, of 5.
Passage of the viruses in HeLa cells
Biological assays. Plaque assays, HAl and neutralization tests were performed as described by Wills et al. (1992) .
Pathogenicity studies. Female outbred (strain TO) white mice (Olac, UK), 3-4 weeks of age and weighing 2~25 g, were used to determine virus pathogenicity. Groups of eight or more mice were inoculated by either the intracerebral (i.c., 20 gl) or intrauasal (i.n., 20 gl) route. Following inoculation, mice were observed for a period of up to 21 days. Where appropriate, mice were sacrificed and their brains were removed, homogenized and then resuspended as a 20 % suspension in PBS. These were stored at -80 °C until assayed for infectivity.
Neuropathology. Mice to be examined for brain pathology were sacrificed by cervical spine dislocation. The brains were removed and fixed whole in 10% neutral buffered formalin for at least 3 days prior to sectioning. Brains were sliced into five blocks of uniform thickness and location using standard landmarks on the base of the brain, except where an i.c. inoculation site was evident in which case the slicing was modified to include that site in one section. Tissue blocks were processed for paraffin embedding and sectioning at 7 gm by standard histologic techniques. Routine staining for histologic examination employed haemotoxylin and eosin (H & E) and luxol fast blue for myelin. Immunochemistry used a mouse polyclonal antisera raised against strain Nakayama, biotinylated secondary antibody and avidinconjugated alkaline phosphatase as chromogen (Ultraprobe, Biomedia Corporation).
Indirect immunofluorescence (IIF) test. IIF was performed as described by Sil et al. (1992a) .
Nucleotide sequence of the JE virus structural protein genes. The viral genomic RNA was extracted from the virus-infected cell cultures or mouse brain as described previously (Ni et al., 1994) . RT PCR, cloning and sequencing were performed as described by Ni et al. (1994) . Computer analyses of the nucleotide and deduced amino acid sequence data were accomplished with the aid of MICROGENIE (Queen & Korn, 1984) and CLUSTAL (Higgins & Sharp, 1988) programs.
Virus receptor-binding assay. Mouse brain membrane receptor preparations (MRPs) were prepared from outbred adult (3-4 weeks of age) female TO strain mice (Olac, UK), based on a method described previously (Middlemiss & Fozard, 1983) . Briefly, the whole brain was rapidly dissected out, weighed and homogenized in 100 ml Tris-HC1 (50 mM, pH 7"6) using a Kinematica Polytron (setting 3 for 30 s). The homogenate was centrifuged at 35 600 g for 10 min and the pellet was resuspended in the same volume of the Tris-HCl buffer. This process was repeated twice. Between the second and third centrifugations, the homogenate was incubated at 37 °C for 10 rain. The final pellet was resuspended in Tris-HC1 buffer (50 mM, pH 7"6) to give a final concentration of approximately 2040 mg wet weight of brain per ml.
The virus-binding assay was performed as follows. The MRP (0-9 ml) at a concentration of 20 mg wet weight of brain per ml and 0 1 ml of the virus preparation containing 106 or 107 p.f.u, were mixed in an Eppendorf tube and incubated in a water bath at 26 °C for 1 h. The tube was gently mixed every 5 min by inversion. After incubation, bound virus was pelleted by centrifugation at 13 000 g for 10 min. The residual virus infectivity in the supernatant was determined by the plaque assay technique described above. The degree to which virus bound to the MRP was expressed as the log10 reduction of the virus titre (log~0 p.f.u./ml) in the supernatant compared to that of the control test, in which the virus was incubated with Tri~HC1 buffer (50 mM, pH 7"6), and was termed a binding index (BI).
The virus-binding inhibition assay was performed using a saturating concentralion of the antagonist ligand spiperone (Research Biochemical Incorporated, UK) which blocks dopamine and serotonin subtype receptors. The procedure for the virus-binding inhibition assay was the same as the virus-binding assay described above except that the mouse brain MRP was pre-incubated with 10 gM (final concentration) of the receptor antagonist ligand at 37 °C for 10 min.
Results

Passage of wild-type strains of JE virus in HeLa cells
Wild-type strains of JE virus, SA14, Beijing-1, Nakayama-O and 826309 (hereafter termed HeLa p0 viruses), were used to infect HeLa cells (Table 1 ). All four strains of JE virus produced significant CPE throughout all HeLa cell passages. Furthermore, the infectivity titre of each HeLa cell-passaged virus remained at a high level, except for the SA14 virus, whose infectivity titre decreased at passages 5 and 6. For Nakayama-O, Beijing-1 and 826309 viruses an m.o.i, of 5 was maintained throughout the HeLa passage series and the infectivity yield was maintained at 500-1000 p.f.u, per cell. In the case of SA 14 virus, the m.o.i, was reduced to 1 or less after passage 1 and the infectivity yield was reduced to 0"3 p.f.u, per cell at HeLa passage 6. The infectivity titre of HeLa cell-passaged JE virus was determined by plaque assay using both LLC-MK2 and HeLa cells and no significant difference was found (data not shown).
HA activity of the HeLa pO and HeLa-passaged JE viruses
The four parental JE HeLa p0 viruses which had been grown in mosquito C6/36 cells had infectivity titres of 10~-107 p.f.u./ml and HA titres of 640--2560 units per ml (Table 1) . However, after a single passage in HeLa cells there was no detectable HA activity even though infectivity yields increased at least 10-fold for all four viruses compared to non-HeLa passaged parent viruses. Although this loss of HA activity could be attributed to insufficient antigen available for some JE HeLa cellpassaged viruses (e.g. the HeLa p5 and p6 SA14 viruses), there was no detectable HA activity for the other HeLa cell-passaged JE viruses, even though the majority of the infectivity titres were higher than the respective parental HeLa p0 virus. All the JE HeLa p6 viruses were found to retain high infectivity and regain HA activity following 
Virulence of HeLa cell-passaged JE viruses for mice following i.n. inoculation
The virulence of the four HeLa cell-passaged wild-type strains of JE virus was determined and compared to that of the HeLa p0 viruses in adult mice following i.n. inoculation (i.e. neuroinvasiveness) ( Table 2) . Six sequential HeLa cell passages of JE virus strain Nakayama-O resulted in significant attenuation of the virus. The p.f.u./LDs0 ratio of the HeLa p0 virus was 102.8 following i.n. inoculation, whereas it was greater than 10 ~3 after six HeLa cell passages. Thus, the virulence of the Nakayama-O HeLa p6 virus was attenuated at least 3500-fold. Similarly, strain 826309 also showed a marked attenuation after six passages in HeLa cells. The p.f.u./LDs0 of the 826309 HeLa p6 virus was at least 100-fold higher than that of the HeLa p0 virus (10 ~3 versus >~ 10~). In contrast, the Beijing-1 strain remained as virulent for mice after six HeLa cell passages as the HeLa p0 parent virus. As reported previously (Huang, 1982) , the SA14 strain had very low neuroinvasiveness and was completely avirulent (i.e. no clinical manifestations of the disease were observed) following i.n. inoculation of adult mice. Therefore, it was not possible to determine the neuroinvasiveness of either the HeLa p6 or the HeLa p0 viruses by this peripheral route of challenge.
HeLa and non-HeLa-passaged JE virus
To examine the attenuation process, the intermediate HeLa cell-passaged Nakayama-O viruses were inoculated as described above into adult mice. The results (Table 2) show that this virus exhibited significant attenuation after a single passage in HeLa cells, and did not kill mice following i.n. inoculation of 106 p.f.u., whereas the parent virus did. This attenuated phenotype was maintained during subsequent passages in HeLa cells.
Virulence of HeLa cell-passaged JE viruses for mice following i.c. inoculation
The studies described above indicate that neuroinvasiveness of JE virus is lost following passage in HeLa cells. To examine neurovirulence, the virus was inoculated into adult mice by the i.c. route. The Nakayama-O HeLa p0 virus was lethal for all mice following i.c. inoculation of 10 p.f.u, of the virus. In contrast, the HeLa p 1 and p6 viruses were not lethal, even following the inoculation of 105 p.f.u, by the i.c. route. Moreover, no infectious virus, detectable by plaque assay (~< 10 ~~ p.f.u, per brain), was found in brain samples collected on days 1, 2, 6, 7, 14 and 21 post-infection from the mice inoculated i.c. with the HeLa pl and p6 viruses, whereas high titre virus (10 TM p.f.u, per brain) was recovered from mouse brain inoculated with the p0 virus on day 6/7 post-infection. Also, no viral RNA was detectable by RT-PCR of RNA (462 bases at the 5' terminus of the E protein gene) from the brains of mice harvested on days 1 and 2 post-infection with Nakayama HeLa p6 virus.
As there was no detectable virus in the brains of HeLa p6-infected mice, brains were harvested on day 7 postinfection from mice infected with Nakayama-O HeLa p0 and Nakayama HeLa p6 viruses and were examined for pathological lesions. Mice given the parent non-HeLapassaged Nakayama virus showed typical JE virusinduced pathology and evidence of inflammation and virus antigen was detected by immunohistochemistry. In contrast, the HeLa p6 virus-infected mice had evidence of inflammation and necrosis, particularly at the site of the i.c. inoculation, but no virus antigen was detected by immunohistochemistry (data not shown).
Due to the poor peripheral virulence (or neuroinvasiveness) of strain SA 14, the neurovirulence of HeLa p0 and HeLa-passaged SA-14 virus was determined following i.c. inoculation. It was found that both the HeLa p0 and p6 viruses were lethal for mice following i.c. inoculation of doses of 10-105 p.f.u. No difference in the average survival time was observed between mice infected with either the HeLa p0 or HeLa p6 viruses.
Nakayama-O HeLa p6 virus remains attenuated after passage in other cell lines
It has been shown above that the HeLa cell-passaged JE viruses could regain HA activity following a single passage in mosquito C6/36 cells. It was possible that the recovery of HA activity by passaging the attenuated virus in mosquito or other cell cultures would cause a reversion to virulence. In an attempt to answer this question, the attenuated Nakayama-O HeLa p6 virus was passaged once either in the C6/36 cell line, LLC-MK2 or primary CEF cell culture. The virulence and HA activity of the Nakayama-O HeLa p6 virus grown in the above cell cultures were determined (Table 3) .
The virus infectivity titre determined by plaque assay Table 4 show that the Nakayama-O HeLa p6 virus passaged in C6/36, CEF (HA positive) and LLC-MK2 (HA negative) cells remained avirulent. The CEF-passaged Nakayama-O HeLa p6 virus was also avirulent following i.c. inoculation of 105 p.f.u, into adult mice. Furthermore, no infectious virus was detected (~< 102.5 p.f.u, per brain) in brains sampled from the mice on days 6/7, 10 and 14 post-inoculation.
Reactivity of HeLa pO and HeLa-passaged JE viruses with a panel of JE wild-type and vaccine-specific MAbs
The HeLa p0 and HeLa-passaged JE viruses were examined by IIF tests with a panel of JE wild-type and vaccine-specific MAbs (Sil et al., 1992a) . The results are shown in Table 4 . Of the five wild-type-specific MAbs, K 13 and K39 did not recognize the attenuated Nakayama-O and 826309 HeLa p6 viruses but were still reactive with the virulent Beijing-1 and SA14 HeLa p6 viruses. The other three wild-type-specific MAbs, K10, K43 and J44, recognized both the virulent and the attenuated HeLa p6 JE viruses. One vaccine-specific MAb, V23, reacted with the Nakayama-O and 826309 HeLa p6 viruses but not the other HeLa cell-passaged wild-type JE viruses, whereas another vaccine-specific MAb, T60, did not recognize any HeLa cell-passaged viruses examined in this study. Further examination of the intermediate HeLa cellpassaged Nakayama-O viruses showed that MAbs K13 and K39 only recognized a few infected cells at the first HeLa cell passage and became completely negative with the second passage. On the other hand, the vaccinespecific MAb V23 was reactive with some of the Nakayama-O virus-infected cells from the first Hela cell passage and recognized all infected cells from the second passage onwards.
Binding activity of Nakayama-O HeLa pO and HeLa p6 viruses to mouse brain receptor preparations
In a separate study we found that the attenuated SA14 series vaccine strains (SA14-2-8, SA14-5-3 and SA14-14-2) demonstrated different mouse brain receptor-binding activities from their wild-type parent strain SA14 (manuscript in preparation). Hence, the MRP binding activity of the attenuated Nakayama-O HeLa p6 virus was compared to that of its virulent parent HeLa p0 virus. Both the virulent Nakayama-O HeLa p0 and attenuated HeLa p6 derivative bound to the mouse brain MRPs with similar BI (Table 5) .
We found that the dopamine and serotonin receptor subtype antagonist spiperone could inhibit the binding of wild-type SA 14, but not its attenuated vaccine derivatives (SA14-2-8, SA-14-5-3 and SA14-14-2), to mouse brain MRPs. Following pre-incubation of the MRP with 10 gM spiperone, it was found that the virulent parent virus Nakayama-O HeLa p0, but not the attenuated HeLa p6 virus, was prevented from binding to the MRP. Controls demonstrated that both viruses bound to the MRP to a similar degree in the absence of spiperone (Table 5) .
Nucleotide sequences of the structural protein genes of the attenuated HeLa p6 viruses
The nucleotide sequence of 2463 nucleotides in the 5' non-coding region and structural protein genes of the attenuated HeLa p6 viruses and their HeLa p0 parent viruses was determined. Nakayama-O HeLa p6 virus ~: Values represent virus infectivity titre expressed as log~o p.f.u./ml. (Table 6) whereas 826309 HeLa p6 virus differed from its parent HeLa p0 virus by 37 nucleotides coding for eight amino acid substitutions (Table 6 ). The only common amino acid substitution was at E-366 where the alanine in the parent HeLa p0 virus was replaced by valine in the HeLa-attenuated viruses. Nevertheless, comparison of the M and E protein sequences of the two HeLa p6 viruses revealed that they were identical, except at E-133, indicating that attenuation of JE virus by passage in HeLa cells was selecting for viruses with a particular M and E protein amino acid sequence. Support for this hypothesis came from passage of the same non-HeLapassaged Nakayama seed virus in monkey kidney Vero E6 cells. One passage of Nakayama virus in Vero cells resulted in loss of HA activity and attenuation of mouse virulence, i.e. the same phenotype as HeLa-passaged Nakayama virus. The E protein amino acid sequence of the Vero pl virus was found to have the same substitutions at E-133, E-209 and E-366 as the HeLa p6 virus.
The Nakayama HeLa p6 virus that received one additional passage in mosquito C6/36 cells and regained HA activity was also examined. Four hundred and six nucleotides in the M and E protein genes were sequenced and found to differ at 12 nucleotides coding for 5 amino acid substitutions. This virus was not examined further as the high mutation rate did not enable substitutions involved in HA activity to be identified.
Discussion
It was found that the prototype JE virus strain, Nakayama-O, and an Indian strain, 826309, were significantly attenuated for neurovirulence and neuroinvasiveness in mice following six passages in HeLa cells. In contrast, the Beijing-1 and SA-14 HeLa p6 viruses remained as virulent as the HeLa p0 parent viruses following i.n. (Beijing-1) and i.c. (SA-14) inoculation of mice. The prototype strain Nakayama-O, which is the basis of the currently used inactivated JE vaccine, was selected for further analysis. The virulence of intermediate HeLa cell-passaged Nakayama-O viruses was also determined by both i.n. and i.c. routes of inoculation. It was found that the neurovirulence and neuroinvasiveness of the Nakayama-O virus were significantly reduced following a single passage in HeLa cells (Tables 2 and 3 ). No infectious virus was recovered from the brains of mice inoculated with the attenuated HeLa p6 virus. This implies that the HeLa cell-attenuated Nakayama-O virus may not be able to infect brain tissues or may only cause a very brief transient infection.
The loss of HA activity of both the attenuated (Nakayama-O and 826309) and virulent (Beijing-1 and SA-14) HeLa cell-passaged JE viruses occurred at the first passage. This implies that the biological function of the haemagglutinin epitopes on the E protein of JE viruses may have been modified genetically or conformationally by the lipid composition of HeLa cell membranes (from which the viral membrane was derived). Following a single passage in an invertebrate cell line, C6/36, or CEF cells, the Nakayama HeLa p6 virus regained HA activity. In contrast, this function was not recovered after the virus had been passaged once in the vertebrate cell line, LLC-MK2. Examination of the pathogenicity of Nakayama-O HeLa p6 virus passaged in C6/36, LLC-MK2 or CEF cells showed that the attenuation characteristics appeared to be stable for at least one non-HeLa cell passage. Therefore, based on the present study, it is proposed that the HA activity of the JE viruses examined is not necessarily associated with attenuation and/or virulence.
By examination of all the HeLa cell passage levels of the Nakayama-O virus (HeLa pl-p6) and the 826309 HeLa p6 virus with a panel of JE wild-type-specific and vaccine-specific MAbs (Sil et al., 1992a) , it was observed that the attenuation of JE Nakayama-O and 826309 viruses was accompanied by antigenic changes in the E protein. The JE wild-type-specific MAbs (K13 and K39) recognized the HeLa p0 parental virus but not the attenuated HeLa p6 virus. In contrast, one vaccinespecific MAb (V23) reacted with the live-attenuated vaccine strains (SA14-2-8, SA14-5-3 and SA14-14-2) as well as the JE Nakayama-O and 826309 HeLa p6 viruses but not the parental HeLa p0 viruses. Thus, wild-type epitopes on the E protein were lost and at least one vaccine-specific epitope was gained during the passaging of the Nakayama-O and 826309 viruses in HeLa cells. Further studies showed that the loss of wild-type epitopes and the acquisition of a vaccine-specific epitope occurred during the first HeLa passage of the Nakayama-O virus, became stable from the second passage onwards and were co-incident with attenuation of neurovirulence in mice. Similar observations were described by Barrett et al. (1990) and Sil et al. (1992b) , who reported that HeLa cell-attenuated yellow fever viruses lost wild-type epitopes and gained a vaccine-specific epitope on the E protein. Thus, antigenic markers of attenuation and virulence on the E protein appear to be associated with attenuation of mosquito-borne flaviviruses following passage in HeLa cells.
The altered epitope profile on the E protein was accompanied by a functional change in that the attenuated Nakayama-O HeLa p6 virus demonstrated different receptor-binding activity to that of its parent Nakayama-O HeLa p0 virus. Spiperone, an antagonist for dopamine and serotonin receptor subtypes, was found to block the virulent Nakayama-O HeLa p0 viruses, but not the attenuated HeLa p6 viruses, binding to the mouse brain MRP. Thus, six passages of the JE Nakayama-O virus in HeLa cells engendered attenuation of the virus with the acquisition of three biological markers which are shared with the SA14 series vaccine strains: (1) significantly reduced neuroinvasiveness and/or neurovirulence for mice; (2) loss of one or more wild-type epitopes and gain of a vaccine-specific epitope; and (3) altered receptor-binding activity, probably due to alteration of the receptor-binding site by mutation in the E protein (Sil et aI., 1992 a; Wills et al., 1992) .
Nucleotide sequencing of approximately 25 % of the genomes of Nakayama-O HeLa p6 and 826309 HeLa p6 viruses and comparison with the parent HeLa p0 viruses revealed a large number of nucleotide changes and amino acid substitutions. In fact, six passages in HeLa cells resulted in more nucleotide and amino acid changes in the structural protein genes than 123 passages of strain SA14 in PHK cell culture to generate vaccine strain SA14-14-2 (12 nucleotide changes coding for nine amino acid substitutions) (Nitayaphan et al., 1990; Ni et al., 1995) . Therefore, passage of wild-type JE virus in HeLa cells selected for a variant with many mutations. However, it is significant that the M and E protein sequences of the two attenuated HeLa p6 viruses are identical (except for E-133). Also, Nakayama virus after one passage in Vero cells is identical in phenotype (loss of HA activity and attenuation of virulence) and E protein amino acid sequence to virus found after six passages in HeLa cells. On the basis of these results we cannot distinguish between single or multiple genetic determinants of JE virus attenuation of neurovirulence and loss of HA activity. However, it appears that passage in HeLa cells is selecting for viruses with defined M and E protein amino acid sequences. Presumably this combination of amino acids is important in the attenuation process. The only common HeLa p6 virus amino acid substitution was E-366, which is a variable amino acid in wild-type JE virus strains (Ni et al., 1994) . Wild-type strains with differences at E-366 were still neurovirulent in adult mice (Wills et al., 1992) , indicating that this amino acid is not directly involved in attenuation. However, Hasegawa et al. (1992) reported that a combination of amino acid changes at E-52, E364 and E-367 affected early virus~ell interaction and virulence in mice, indicating that mutations at E-363 and E-366 of HeLa p6 virus may contribute to attenuation. Nonetheless, it is likely that virulence is multifactorial and involves nucleotides in the 75 % of the genome of Nakayama HeLa p6 virus that was not sequenced.
The common E protein amino acid sequence of the attenuated Nakayama-O and 826309 HeLa-passaged variants may explain why these viruses share the same vaccine-specific epitope (recognized by MAb V23). The epitope is probably conformational as it is also found on the SA14 series vaccine strains which have no conservative amino acid changes in the E protein with the HeLa-passaged viruses (Ni et al., 1994) .
In conclusion, the results presented in this paper provide more information contributing to an understanding of the molecular basis of attenuation and/or pathogenicity of JE virus. However, the large number of nucleotide and amino acid changes in the region of the genome of the JE HeLa p6 viruses that was sequenced indicate that the HeLa cell attenuation system cannot be easily utilized to identify the molecular basis of attenuation of JE virus.
